HealthQuill . Gilead Sciences Inc.
Gilead Sciences, Inc.’s twice-yearly injectable drug for the prevention of HIV in adults and adolescents got approval from the US regulator.
Uncategorized

Gilead’s Yeztugo drug for HIV prevention in adults gets FDA nod

HQ Team June 19, 2025: Gilead Sciences, Inc.’s twice-yearly injectable drug for the prevention of HIV in adults and adolescents got approval from.

Read More
The US drug regulator has put on hold two trials of Gilead Sciences Inc., testing a combination of two of its investigational HIV treatments, after some patients developed lower immune cell counts.
Drugs Health Pharma

Gilead Sciences’ HIV experimental trials put on hold by US drug regulator

HQ Team June 11, 2025: The US drug regulator has put on hold two trials of Gilead Sciences Inc., testing a combination of.

Read More
An investigational therapy from Kite Pharma Inc., a Gilead Sciences company, has reduced tumours in 62% of the patients with a fatal form of brain cancer.
Drugs Health Pharma

Gilead unit’s experimental therapy shrink brain tumours by 62%

HQ Team June 2, 2025: An investigational therapy from Kite Pharma Inc., a Gilead Sciences company, has reduced tumours in 62% of the.

Read More
Merck & Co., Inc.’s drug Keytruda, along with Gilead Sciences Inc.'s antibody-drug conjugate, cut the risk of an aggressive breast cancer advancement and death by 35% during an end-stage trial.
Drugs Health Pharma

Merck, Gilead’s drug for breast cancer cuts progression risk by 35 per cent

HQ Team June 1, 2025: Merck & Co., Inc.’s drug Keytruda, along with Gilead Sciences Inc.’s antibody-drug conjugate, cut the risk of an.

Read More
US-based Merck Inc., two late-stage studies have met the main efficacy goal of suppressing the HIV-1 virus in adults receiving different antiretroviral therapies, according to a company statement.
Drugs Health Medical Pharma

Merck’s end-stage studies meet efficacy goal of suppressing HIV-1 virus

US-based Merck Inc., two late-stage studies have met the main efficacy goal of suppressing the HIV-1 virus in adults receiving different antiretroviral therapies,.

Read More
Merck & Co., Inc., and Gilead Sciences, Inc.’s investigational combinational drug for HIV treatment, put on clinical hold last year, has met a secondary goal of a ‘high’ viral suppression rate in adults.
Drugs Health Pharma

Gilead, Merck’s HIV experimental drug scores ‘high’ on viral suppression

Merck & Co., Inc., and Gilead Sciences, Inc.’s investigational combinational drug for HIV treatment, put on clinical hold last year, has met a.

Read More